|
AU695869B2
(en)
|
1993-04-06 |
1998-08-27 |
Fred Hutchinson Cancer Research Center |
Chimeric cytokine receptors in lymphocytes
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US8034332B2
(en)
|
1997-04-30 |
2011-10-11 |
Conkwest, Inc. |
Interleukin-secreting natural killer cell lines and methods of use
|
|
EP1007630B1
(en)
|
1997-04-30 |
2006-04-19 |
Hans Klingemann |
Natural killer cell lines and methods of use
|
|
US6645490B2
(en)
*
|
1998-03-02 |
2003-11-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
AU1072701A
(en)
|
1999-10-04 |
2001-05-10 |
Chiron Corporation |
Cd40 antagonist for treating psoriasis
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
EP2009027B1
(en)
|
2001-04-27 |
2014-05-21 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-CD40 monoclonal antibody
|
|
AU2002257420A1
(en)
|
2001-05-01 |
2002-11-11 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
CN100379762C
(zh)
|
2003-12-08 |
2008-04-09 |
中国人民解放军军事医学科学院生物工程研究所 |
人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
|
|
RU2377254C2
(ru)
|
2003-12-25 |
2009-12-27 |
Кирин Фарма Кабусики Кайся |
Мутанты анти-cd40 антитела
|
|
US7674621B2
(en)
|
2004-05-21 |
2010-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Plasmids and phages for homologous recombination and methods of use
|
|
US7618817B2
(en)
|
2004-07-10 |
2009-11-17 |
Fox Chase Cancer Center |
Genetically modified human natural killer cell lines
|
|
WO2006076742A2
(en)
|
2005-01-16 |
2006-07-20 |
Georgia Tech Research Corporation |
Methods and compositions for increasing membrane permeability
|
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
GEP20125628B
(en)
|
2006-04-21 |
2012-09-10 |
Novartis Ag |
Pharmaceutical compositions containing antagonist anti-cd40 antibody
|
|
CA2657821A1
(en)
|
2006-07-21 |
2008-01-24 |
Gilead Sciences, Inc. |
Aza-peptide protease inhibitors
|
|
US20090025274A1
(en)
|
2007-07-23 |
2009-01-29 |
Tim Lail |
Animal trap
|
|
GB0815216D0
(en)
*
|
2008-08-21 |
2008-09-24 |
Asterion Ltd |
Interleukin
|
|
ES2592216T3
(es)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
|
|
RS60612B1
(sr)
|
2010-03-31 |
2020-08-31 |
Boehringer Ingelheim Int |
Anti-cd40 antitela
|
|
US8734774B2
(en)
|
2010-04-02 |
2014-05-27 |
University Of Rochester |
Protease activated cytokines
|
|
HUE040213T2
(hu)
|
2010-06-11 |
2019-02-28 |
Kyowa Hakko Kirin Co Ltd |
Anti-TIM antitest
|
|
ES2734076T3
(es)
|
2011-02-17 |
2019-12-04 |
Kyowa Hakko Kirin Co Ltd |
Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
|
|
CN103635488B
(zh)
|
2011-04-29 |
2016-12-14 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
EP2785375B1
(en)
|
2011-11-28 |
2020-07-22 |
Merck Patent GmbH |
Anti-pd-l1 antibodies and uses thereof
|
|
WO2013177187A2
(en)
*
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
|
EP2914627B1
(en)
|
2012-10-30 |
2021-04-07 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
|
WO2014124143A1
(en)
|
2013-02-06 |
2014-08-14 |
Anthrogenesis Corporation |
Modified t lymphocytes having improved specificity
|
|
KR20160013049A
(ko)
|
2013-06-03 |
2016-02-03 |
노파르티스 아게 |
항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
|
|
KR20170018450A
(ko)
|
2014-06-18 |
2017-02-17 |
케모테라포이티쉐스 포르슝스인스티투트 게오르크-스파이어-하우스 |
세포 치료제로서의 car-발현 nk-92 세포
|
|
EP3309174B1
(en)
|
2014-07-11 |
2022-05-11 |
Ventana Medical Systems, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
CN107001475B
(zh)
|
2014-11-06 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
抗tim3抗体及使用方法
|
|
US10336810B2
(en)
*
|
2015-02-12 |
2019-07-02 |
University Health Network |
Chimeric antigen receptors, encoding nucleic acids and methods of use thereof
|
|
EP3265486A4
(en)
|
2015-03-06 |
2018-11-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
KR102751730B1
(ko)
|
2015-03-27 |
2025-01-10 |
이뮤너티바이오, 인크. |
암의 치료를 위한 유전적으로 변형된 nk-92 세포 및 모노클로날 항체
|
|
WO2016172010A1
(en)
|
2015-04-20 |
2016-10-27 |
Effector Therapeutics, Inc. |
Inhibitors of immune checkpoint modulators for use in treating cancer and infections
|
|
AR105444A1
(es)
|
2015-07-22 |
2017-10-04 |
Sorrento Therapeutics Inc |
Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
|
PE20180773A1
(es)
|
2015-10-02 |
2018-05-07 |
Hoffmann La Roche |
Anticuerpos biespecificos para pd1 y tim3
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
JP7198670B2
(ja)
*
|
2016-04-20 |
2023-01-04 |
フレッド ハッチンソン キャンサー センター |
免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
|
|
MA55697A
(fr)
|
2016-05-18 |
2022-02-23 |
Boehringer Ingelheim Int |
Molécules d'anticorps pour le traitement du cancer
|
|
AU2017297506A1
(en)
|
2016-07-14 |
2019-02-21 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
|
MA47694A
(fr)
|
2017-02-28 |
2021-05-19 |
Seagen Inc |
Anticorps anti-tigit
|
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
|
EP3679145A2
(en)
|
2017-09-08 |
2020-07-15 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
|
|
AU2019324170A1
(en)
|
2018-08-23 |
2021-02-18 |
Seagen, Inc. |
Anti-TIGIT antibodies
|
|
US20240207405A1
(en)
|
2021-04-28 |
2024-06-27 |
The General Hospital Corporation |
Il2 tethered to its receptor il2rbeta and pore-forming proteins as a platform to enhance immune cell activity
|